Minocycline vs. tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori rescue treatment: a multicentre, randomized controlled trial

被引:12
|
作者
Huang, Yu [1 ]
Chen, Jinnan [1 ]
Ding, Zhaohui [1 ]
Chen, Xi [1 ]
Liang, Xiao [1 ]
Zeng, Xin [2 ]
Xu, Fei [2 ]
Han, Yuehua [3 ]
Lu, Hong [1 ]
机构
[1] Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Inst Digest Dis, Div Gastroenterol & Hepatol,Sch Med,NHC Key Lab Di, Shanghai, Peoples R China
[2] Tongji Univ, Shanghai East Hosp, Dept Gastroenterol, Sch Med, Shanghai, Peoples R China
[3] Zhejiang Univ, Dept Gastroenterol, Affiliated Hosp 2, Sch Med, Hangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
Helicobacter pylori; Minocycline; Tetracycline; Rescue therapy; ANTIBIOTIC-RESISTANCE; 2ND-LINE REGIMENS; AMOXICILLIN; METRONIDAZOLE; ERADICATION; DOXYCYCLINE; INFECTION; EFFICACY; SAFETY; SUSCEPTIBILITY;
D O I
10.1007/s00535-023-01991-y
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BackgroundTo compare the efficacy and tolerability of minocycline vs. tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori (H. pylori) rescue treatment.MethodsThis study was a multi-center, randomized-controlled, non-inferiority trial. Refractory H. pylori-infected subjects with multiple treatment-failure were randomly (1:1) allocated to receive 14-day therapy with esomeprazole 20 mg b.i.d, bismuth 220 mg b.i.d, plus metronidazole 400 mg q.i.d and minocycline 100 mg b.i.d (minocycline group) or tetracycline 500 mg q.i.d (tetracycline group). Primary outcome was H. pylori eradication rate evaluated by C-13-urea breath test at least 6 weeks after the end of treatment. Antibiotic resistance was determined using E test method.ResultsThree hundred and sixty-eight subjects were randomized. The eradication rates in minocycline group and tetracycline group were 88.0% (162/184, 95% CI 83.3-92.8%) and 88.6% (163/184, 95% CI 83.9-93.2%) in intention-to-treat analysis, 98.0% (149/152, 95% CI 95.8-100%) and 97.4% (150/154, 95% CI 94.9-99.9%) in per-protocol analysis, 93.1% (162/174, 95% CI 89.3-96.9%) and 93.1% (163/175, 95% CI 89.4-96.9%) in modified intention-to-treat analysis. Minocycline, tetracycline and metronidazole resistance rates were 0.7%, 1.4% and 89.6%, respectively. Non-inferiority of minocycline was confirmed (P < 0.025). Metronidazole resistance did not affect the efficacy of either therapy. The two therapies exhibited comparable frequencies of adverse events (55.4% vs. 53.3%); almost half of them were mild. Dizziness was the most common adverse events in the minocycline group.ConclusionsMinocycline can be an alternative for tetracycline in bismuth-containing quadruple therapy for H. pylori empirical rescue treatment, irrespective of metronidazole resistance. However, relatively high incidence of adverse events in both regimens should be emphasized.
引用
收藏
页码:633 / 641
页数:9
相关论文
共 50 条
  • [41] Comparison of bismuth-containing quadruple and concomitant therapies as a first-line treatment option for Helicobacter pylori
    Uygun, Ahmet
    Kadayifci, Abdurrahman
    Polat, Zulfikar
    Kantarcioglu, Murat
    Kilciler, Guldem
    Baser, Omer
    Ozcan, Ayhan
    Emer, Ozdes
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2012, 23 (01) : 8 - 13
  • [42] Efficacy of levofloxacin, amoxicillin, bismuth-containing quadruple therapy for helicobacter pylori
    Huang, Sijing
    Wang, Chengdang
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 548 - 548
  • [43] Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments
    Gisbert, J. P.
    Romano, M.
    Gravina, A. G.
    Solis-Munoz, P.
    Bermejo, F.
    Molina-Infante, J.
    Castro-Fernandez, M.
    Ortuno, J.
    Lucendo, A. J.
    Herranz, M.
    Modolell, I.
    del Castillo, F.
    Gomez, J.
    Barrio, J.
    Velayos, B.
    Gomez, B.
    Dominguez, J. L.
    Miranda, A.
    Martorano, M.
    Algaba, A.
    Pabon, M.
    Angueira, T.
    Fernandez-Salazar, L.
    Federico, A.
    Marin, A. C.
    McNicholl, A. G.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 41 (08) : 768 - 775
  • [44] Furazolidone-containing triple and quadruple eradication therapy for initial treatment for Helicobacter pylori infection: A multicenter randomized controlled trial in China
    Xie, Yong
    Zhang, Zhenyu
    Hong, Junbo
    Liu, Wenzhong
    Lu, Hong
    Du, Yiqi
    Wang, Weihong
    Xu, Jianming
    Wang, Xuehong
    Huo, Lijuan
    Zhang, Guiying
    Lan, Chunhui
    Li, Xiaoyan
    Li, Yanqing
    Wang, Hong
    Zhang, Guoxin
    Zhu, Yin
    Shu, Xu
    Chen, Ye
    Wang, Jiangbin
    Lu, Nonghua
    HELICOBACTER, 2018, 23 (05)
  • [45] Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial
    Macias-Garcia, Fernando
    Baston-Rey, Iria
    de la Iglesia-Garcia, Daniel
    Calvino-Suarez, Cristina
    Nieto-Garcia, Laura
    Enrique Dominguez-Munoz, Juan
    HELICOBACTER, 2019, 24 (01)
  • [46] Modified quadruple therapy versus bismuth-containing quadruple therapy in first-line treatment of Helicobacter pylori infection in Korea; rationale and design of an open-label, multicenter, randomized controlled trial
    Lim, Hyun
    Bang, Chang Seok
    Shin, Woon Geon
    Choi, Jae Ho
    Soh, Jae Seung
    Kang, Ho Suk
    Yang, Young Joo
    Hong, Ji Taek
    Shin, Suk Pyo
    Suk, Ki Tae
    Lee, Jae Jun
    Baik, Gwang Ho
    Kim, Dong Joon
    MEDICINE, 2018, 97 (46)
  • [47] Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial
    Suo Baojun
    Tian Xueli
    Zhang Hua
    Lu Haoping
    Li Cailing
    Zhang Yuxin
    Ren Xinlu
    Yao Xingyu
    Zhou Liya
    Song Zhiqiang
    中华医学杂志英文版, 2023, 136 (08)
  • [48] Tailored eradication vs empirical bismuth-containing quadruple therapy for first-line Helicobacter pylori eradication: A comparative,open trial
    Youn I Choi
    Jun Won Chung
    Dong Kyun Park
    Kyoung Oh Kim
    Kwang An Kwon
    Yoon Jae Kim
    Ja Young Seo
    World Journal of Gastroenterology, 2019, (46) : 6743 - 6751
  • [49] Moxifloxacin-Containing Triple Therapy versus Bismuth-Containing Quadruple Therapy for Second-Line Treatment of Helicobacter pylori Infection: A Meta-Analysis
    Wu, Cheng
    Chen, Xiao
    Liu, Jing
    Li, Ming-Yang
    Zhang, Zi-Qi
    Wang, Zhi-Qiang
    HELICOBACTER, 2011, 16 (02) : 131 - 138
  • [50] Vonoprazan is noninferior to proton pump inhibitors in bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: A propensity score matching analysis
    Wang, Juan
    Li, Yue Yue
    Lin, Min Juan
    Liu, Jing
    Lin, Bo Shen
    Ding, Yu Ming
    Wan, Meng
    Zhang, Wen Lin
    Kong, Qing Zhou
    Wang, Shao Tong
    Mu, Yi Jun
    Duan, Miao
    Han, Zhong Xue
    Zuo, Xiu Li
    Li, Yan Qing
    JOURNAL OF DIGESTIVE DISEASES, 2023, 24 (01) : 19 - 27